Vaccine development targeting lipopolysaccharide structure modification

Microbes Infect. 2018 Oct-Nov;20(9-10):455-460. doi: 10.1016/j.micinf.2017.11.006. Epub 2017 Dec 9.

Abstract

Vaccines are one of the most important methods for preventing infectious disease. Structural modification of lipopolysaccharide (LPS) provides a strategy for the development of live attenuated vaccines, either by altering the immunogenicity or by attenuating virulence of the bacteria. This review summarizes various approaches that utilize LPS mutants as whole-cell vaccines.

Keywords: Brucella; Lipopolysaccharide; Vaccine.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Bacterial Vaccines / chemistry*
  • Bacterial Vaccines / genetics
  • Bacterial Vaccines / immunology*
  • Gram-Negative Bacteria / immunology*
  • Humans
  • Lipid A / chemistry
  • Lipid A / immunology
  • Lipopolysaccharides / chemistry*
  • Lipopolysaccharides / genetics
  • Lipopolysaccharides / immunology*
  • Mutation
  • O Antigens / chemistry
  • O Antigens / immunology
  • Oligosaccharides / chemistry
  • Oligosaccharides / immunology
  • Vaccines, Attenuated / chemistry
  • Vaccines, Attenuated / genetics
  • Vaccines, Attenuated / immunology

Substances

  • Bacterial Vaccines
  • Lipid A
  • Lipopolysaccharides
  • O Antigens
  • Oligosaccharides
  • Vaccines, Attenuated